Cargando…

Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests

BACKGROUND: Fabry disease is a rare disorder caused by a large variety of mutations in the gene encoding lysosomal alpha-galactosidase. Many of these mutations are unique to individual families. Fabry disease can be treated with enzyme replacement therapy, but a promising novel strategy relies on sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreotti, Giuseppina, Citro, Valentina, De Crescenzo, Agostina, Orlando, Pierangelo, Cammisa, Marco, Correra, Antonella, Cubellis, Maria Vittoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216245/ https://www.ncbi.nlm.nih.gov/pubmed/22004918 http://dx.doi.org/10.1186/1750-1172-6-66

Ejemplares similares

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

A thermodynamic assay to test pharmacological chaperones for Fabry disease()
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study
por: Andreotti, Giuseppina, et al.
Publicado: (2010)

Drug repositioning can accelerate discovery of pharmacological chaperones
por: Hay Mele, Bruno, et al.
Publicado: (2015)

Identification and analysis of conserved pockets on protein surfaces
por: Cammisa, Marco, et al.
Publicado: (2013)

The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations
por: Citro, Valentina, et al.
Publicado: (2016)

Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease
por: Citro, Valentina, et al.
Publicado: (2016)

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones
por: Monticelli, Maria, et al.
Publicado: (2022)

Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations
por: Liguori, Ludovica, et al.
Publicado: (2020)

Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease
por: Lukas, Jan, et al.
Publicado: (2020)

β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG
por: Monticelli, Maria, et al.
Publicado: (2019)

Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

Pharmacological chaperone therapy for Fabry disease
por: ISHII, Satoshi
Publicado: (2012)

E-Learning for Rare Diseases: An Example Using Fabry Disease
por: Cimmaruta, Chiara, et al.
Publicado: (2017)

A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
por: Citro, Valentina, et al.
Publicado: (2017)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Challenging popular tools for the annotation of genetic variations with a real case, pathogenic mutations of lysosomal alpha-galactosidase
por: Cimmaruta, Chiara, et al.
Publicado: (2018)

The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers
por: Citro, Valentina, et al.
Publicado: (2018)

Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease
por: Seemann, Susanne, et al.
Publicado: (2020)

Data on the inhibition of cell proliferation and invasion by the D2A-Ala peptide derived from the urokinase receptor
por: Furlan, Federico, et al.
Publicado: (2019)

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease
por: Monticelli, Maria, et al.
Publicado: (2023)

Taming molecular flexibility to tackle rare diseases
por: Cubellis, Maria Vittoria, et al.
Publicado: (2015)

Looking for protein stabilizing drugs with thermal shift assay
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022)

Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation
por: Andreotti, Giuseppina, et al.
Publicado: (2013)

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
por: Besada, Pedro, et al.
Publicado: (2021)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19
por: Monticelli, Maria, et al.
Publicado: (2021)

A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease
por: Wu, Xiaoyang, et al.
Publicado: (2011)

The molecular function and clinical phenotype of partial deletions of the IGF2/H19 imprinting control region depends on the spatial arrangement of the remaining CTCF-binding sites
por: Beygo, Jasmin, et al.
Publicado: (2013)

Congenital disorders of glycosylation: narration of a story through its patents
por: Monticelli, Maria, et al.
Publicado: (2023)

Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice
por: Xu, Su, et al.
Publicado: (2015)

Conformational Response to Ligand Binding in Phosphomannomutase2: INSIGHTS INTO INBORN GLYCOSYLATION DISORDER
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
por: Müntze, Jonas, et al.
Publicado: (2018)

Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
por: Benjamin, Elfrida R, et al.
Publicado: (2012)

Galactosemia: Towards Pharmacological Chaperones
por: Banford, Samantha, et al.
Publicado: (2021)

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
por: Hughes, Derralynn A, et al.
Publicado: (2017)

Correction: Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Publicado: (2018)

Pharmacological targeting of host chaperones protects from pertussis toxin in vitro and in vivo
por: Ernst, Katharina, et al.
Publicado: (2021)

Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones
por: Underhaug, Jarl, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4689fvrb4jp902j7g4qe4oilk8